Pemvidutide
ALT-801
A dual GLP-1 and glucagon receptor agonist studied in trials for weight management and for metabolic dysfunction-associated steatotic liver disease. The glucagon component is included for its effect on hepatic fat rather than on appetite alone. Not approved.
Tracking and educational reference only, on values you enter yourself. Not medical advice or a dosing recommendation.
Half-life
Not established in a public source. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Investigational; no approved label defines handling.
References
- J Hepatology 2025: effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD
Read the source
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.